A New Concept Workshop will be held by Breast Cancer Trials’ (BCT) 45th Annual Scientific Meeting (ASM) to provide an opportunity for BCT members and non-members to present new research ideas. **The Workshop will be held at Cairns Convention Centre, Cairns QLD from 1.30 pm to 5 pm on Wednesday 24th July 2024.**

The workshop will involve a presentation of selected concepts, followed by discussion and feedback from the audience. The audience will include BCT Scientific Advisory Committee members including Consumer Advisory Panel representatives, senior BCT staff, and other BCT researchers. Presenters will be expected to attend the workshop in person (virtual presentation is not being used).

This workshop is designed to be an opportunity for those with ideas with the potential to become BCT-led clinical trials to present them to the group. These ideas can potentially move forward to a more formal stage of concept development with the support of BCT’s Scientific Advisory Committee.

Concepts are welcomed from all disciplines relevant to breast cancer care, including medical, surgical or radiation oncology, reconstructive surgery, imaging, pathology and the disciplines involved in supportive care.

Submissions are welcome from both BCT members and non-members. However, for all concepts that are approved for ongoing development, applicants must become BCT members (for information on how to become a member please see <https://www.breastcancertrials.org.au/about/become-a-member/>).

Additional information about the BCT trial development process is available at [https://www.breastcancertrials.org.au/research-development](https://www.breastcancertrials.org.au/research-development%20) and to members via the Research section of the website. Refer Clinical Trials/ Investigator Resources tab or via link: [Research Development and Funding.](https://members.breastcancertrials.org.au/research-development-and-funding)

**The closing date for Concept Proposal submission** **is Friday 30th May 2024**.

*Please note: Phase I trials will not generally be considered for conduct and led by BCT unless the science is from the laboratory of a BCT member, drug supply is enabled, and there is a pathway to a Phase II study that will involve BCT.*

**ELIGIBILITY CRITERIA:**

* Fulfils the definition of clinical or translational research that relates to prior, current or the development of future BCT-led breast cancer clinical trials
* Potential to make a significant impact on the care of those affected by breast cancer
* Feasible as research with significant involvement from BCT
* Potentially eligible for competitive funding e.g. NHMRC or Cancer Councils

**PROCESS:**

* Concept submissions will be peer reviewed and reviews provided to applicants
* Up to six concepts will be chosen for presentation, with notification in mid/late June 2024
* BCT will invite a discussant for each presentation
* A critique will be provided by BCT following concept presentation at the workshop on 24th July 2024

|  |  |
| --- | --- |
| C:\Users\cbeckmore\AppData\Local\Microsoft\Windows\INetCache\Content.Word\BCT_LOGO_CMYK.JPG**BCT New Concept Workshop Proposal Form**  **Wednesday 24th July 2024** | |
| **Name of Investigator/Applicant:** |  |
| **Institution:** |  |
| **Email:** |  |
| **Phone/mobile number:** |  |

|  |  |
| --- | --- |
| **Date submitted to BCT:** |  |

|  |  |
| --- | --- |
| **Title of Concept:** |  |

|  |  |  |  |
| --- | --- | --- | --- |
| Concept Proposal Please provide a brief description of your concept *(depending on the nature of the concept, some sections may not be relevant)*. | | | |
| PROPOSAL OUTLINE | | | |
| **Background/Rationale (1 paragraph)** | | | |
|  | | | |
| **Hypothesis/Aim** | | | |
|  | | | |
| **Key Objectives/Endpoints** | | | |
|  | | | |
| **Key Inclusion/Exclusion Criteria** | | | |
|  | | | |
| **Sample Size** | | | |
|  | | | |
| **Intervention(s)** | | | |
|  | | | |
| PHARMACEUTICIAL/DEVICE INVOLVEMENT  Yes – please complete this section  No – continue to Section 3 | | | |
| Name of drug/device involved with this concept? | | |  |
| Is this drug/device currently approved by the TGA, FDA or EMA?  Yes  No\* | | | |
| \* If not approved, what stage of clinical testing is it at? | | | |
|  | | | |
| What pharmaceutical/device company/ies make this agent/device? | |  | |
| Have you had any preliminary discussions with the pharmaceutical/device company/ies to gauge their interest in this concept?  No  Yes – please comment below: | | | |
|  | | | |
| OTHER ORGANISATION INVOLVEMENT Yes – please list other organisations and their involvement below No – continue to Section 4 | | | |
|  | | | |
| DOES THIS CONCEPT RELATE TO (complete as applicable): *Please note eligibility criteria: The concept is expected to relate to prior, current or the development of future BCT-led breast cancer clinical trials* | | | |
| Previous BCT trial(s) (list): |  | | |
| Current BCT trial(s) (list): |  | | |
| Future BCT- sponsored clinical trial proposal: | | | |
|  | | | |
| **BCT’s Role**  In addition to providing feedback, how do you envisage BCT assisting you to realise this concept (check all that apply): | | | |
| Help develop a concept for a potential future pilot project or trial | | | |
| Support a pilot project; how? | | | |
| Coordinate a clinical trial | | | |
| Provide seed funding | | | |
| Provide additional comment on how BCT may assist: | | | |
|  | | | |

Please return this form to [concept@bctrials.org.au](mailto:concept@bctrials.org.au) by **Friday 30th May 2024**.